Loading...
•
Mar 31, 2021
Allakos Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021 and provided a business update.
Key Takeaways
Allakos reported a net loss of $55.6 million in the first quarter of 2021, compared to $27.8 million in the same period in 2020. The company ended the quarter with $615.9 million in cash, cash equivalents and marketable securities.
Announced the acceptance of two oral and five poster presentations at the Digestive Disease Week (DDW) Annual Meeting.
Initiated a randomized, double-blind, placebo-controlled Phase 3 study of lirentelimab in patients with eosinophilic duodenitis.
Topline data from Phase 3 study of lirentelimab in patients with eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) expected in Q4 2021.
Topline data from Phase 2/3 study of lirentelimab in patients with eosinophilic esophagitis (EoE) expected in Q4 2021.
Forward Guidance
Allakos provided updates on upcoming milestones and clinical trials.
Positive Outlook
- Topline data from a randomized, double-blind, placebo-controlled Phase 3 study of lirentelimab in patients with eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) expected in the fourth quarter of 2021.
- Topline data from a randomized, double-blind, placebo-controlled Phase 2/3 study of lirentelimab in patients with eosinophilic esophagitis (EoE) expected in the fourth quarter of 2021.
- Initiation of a randomized, double-blind, placebo-controlled Phase 2/3 study of subcutaneous lirentelimab in patients with EG and/or EoD expected in the second half of 2021.
- Initiation of a Phase 2 study in a non eosinophilic gastrointestinal disease in the second half of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...